Welcome to the e-CCO Library!

DOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAID
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Tadbiri S.*1, Grimaud J.C.2, Peyrin-Biroulet L.3, Filippi J.4, Pariente B.5, Roblin X.6, Buisson A.7, Stefanescu C.8, Trang-Poisson C.9, Altwegg R.10, Marteau P.11, Vaysse T.12, Bourrier A.13, Nancey S.14, Laharie D.15, Allez M.16, Bouhnik Y.8, Amiot A.17

Created: Wednesday, 20 February 2019, 10:36 AM
DOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with Inflammatory Bowel Disease: A post-hoc analysis of the OBSERV-IBD cohort from the GETAID
Year: 2017
Source: ECCO'17 Barcelona
Authors: Tadbiri S.
Vedolizumab, Arthralgia, Perianal disease, other extraintestinal manifestations
Files: 1
DOP025: Tofacitinib for the treatment of ulcerative colitis: analysis of malignancy rates from the OCTAVE clinical programme
Year: 2018
Source: ECCO '18 Vienna
Authors:

G.R. Lichtenstein1, M.A. Ciorba2, G. Rogler3*, D. Quirk4, C.I. Nduaka4, R.D. Pedersen4, N. Lawendy4, G. Chan4, C. Su4, J. Panés5

Created: Thursday, 21 February 2019, 9:14 AM
DOP025: Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the OCTAVE clinical programme
Year: 2018
Source: ECCO'18 Vienna
Authors: Rogler Gerhard
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP026: Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open
Year: 2018
Source: ECCO '18 Vienna
Authors:

B.E. Sands1, A.C. Moss2, A. Armuzzi3*, J.K. Marshall4, J.O. Lindsay5, W.J. Sandborn6, S. Danese7, K. Tsilkos8, N. Lawendy9, H. Zhang9, G.S. Friedman9, G. Chan9, D.W. Krichbaum8, C. Su9

Created: Thursday, 21 February 2019, 9:14 AM
DOP026: Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Stallmach A.*1, Bokemeyer B.2, Axler J.3, Curtis R.4, Ehehalt R.5, Feagan B.6, Geransar P.7, James A.8, Kaviya A.9, Khalid J.M.10, Wolf D.11, Schreiber S.12

Created: Wednesday, 20 February 2019, 10:36 AM
DOP026: The Toll-like-receptor 9 agonist DIMS0150 demonstrates therapeutic efficacy for the patient-reported outcome measures PRO-2 and ClinPRO in moderate-to-severe active ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Atreya*1, S. Bloom2, F. Scaldaferi3, V. Gerardi4, C. Admyre5, A. Karlsson5, T. Knittel5, J. Kowalski5, M. Lukas6, R. Löfberg7, R. Petryka8, R. Schnabel9, U. Seidler10, S. Nancey11, M. Neurath1, C. Hawkey12

Created: Friday, 22 February 2019, 9:49 AM
DOP027: Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib 8-week induction non-responders
Year: 2018
Source: ECCO '18 Vienna
Authors:

B.G. Feagan1, M.C. Dubinsky2, M. Lukas3*, D. Quirk4, C.I. Nduaka4, E. Maller4, N. Lawendy4, C. Kayhan4, W. Wang4, G. Chan4, C. Su4

Created: Thursday, 21 February 2019, 9:14 AM
DOP027: Large scale drug screen reveals benzimidazole anti-helminthics as potential anti-TNF co-therapy
Year: 2016
Source: ECCO'16 DOP
Authors: Wildenberg M.
adalimumab, anti-TNF agents, Crohn's Disease, Ulcerative Colitis, infliximab, mucosal immunology
Files: 1
DOP027: Large-scale drug screen reveals benzimidazole anti-helminthics as potential anti-TNF co-therapy
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Wildenberg*1, A. Levin2, A. Ceroni3, Z. Guo2, F. Bloemendaal2, D. Ebner3, G. van den Brink1

Created: Friday, 22 February 2019, 9:49 AM
DOP027: Long-term efficacy and safety of ustekinumab in refractory Crohn's disease patients: a multicenter retrospective experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Wils P.*1, Bouhnik Y.2, Michetti P.3, Flourie B.4, Brixi H.5, Bourrier A.6, Allez M.7, Duclos B.8, Serrero M.9, Buisson A.10, Amiot A.11, Fumery M.12, Roblin X.13, Peyrin-Biroulet L.14, Filippi J.15, Bouguen G.16, Abitbol V.17, Coffin B.18, Simon M.19, Laharie D.20, Pariente B.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP027: Long-term efficacy and safety of ustekinumab in refractory Crohn’s Disease patients: A multicenter retrospective experience
Year: 2017
Source: ECCO'17 Barcelona
Authors: Wils P.
Crohn's disease, Anti-TNF agents, Ustekinumab
Files: 1
DOP028: 2nd N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn’s Disease or Ulcerative Colitis
Year: 2018
Source: ECCO'18 Vienna
Authors: Kemp Karen
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP028: Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatment
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bian S.*1, Tang H.T.1, Peeters M.1, Compernolle G.1, Dreesen E.1, Van Assche G.2, Ferrante M.2, Vermeire S.2, Gils A.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP028: Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatment
Year: 2017
Source: ECCO'17 Barcelona
Authors: Bian S.
Anti drug antibodies, Vedolizumab, Immunology
Files: 1
DOP028: Efficacy and safety of biosimilar infliximab after one year: results from a prospective nationwide cohort
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Gecse*1, Z. Vegh1, Z. Kurti1, M. Rutka2, K. Farkas2, J. Banai3, L. Bene4, B. Gasztonyi5, P. A. Golovics1, T. Kristof6, L. Lakatos7, P. Miheller8, F. Nagy9, K. Palatka10, M. Papp11, L. Lakner12, A. Patai13, A. Salamon14, T. Szamosi3, Z. Szepes9, B. Szalay15, G. T. Toth16, A. Vincze17, T. Molnar2, P. Lakatos1

Created: Friday, 22 February 2019, 9:49 AM
DOP028: Efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort
Year: 2016
Source: ECCO'16 DOP
Authors: Gecse K.
anti-TNF, biosimilars, infliximab
Files: 1